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INTRODUCTION
Autoimmune hepatitis (AIH) is a rare, chronic disease associated
with the development of cirrhosis and premature mortality.
Current guidelines state that patients with AIH should receive
induction therapy with corticosteroids or the combination of
corticosteroids/azathioprine, followed by maintenance therapy
with lower doses of steroids and/or azathioprine (1–3). However,
the optimal strategy for the ongoing treatment beyond this point
remains unclear.
The critical decision becomes, should immunosuppression
therapy be continued or withdrawn? On the one hand, liver-
related complications and mortality in AIH are strongly associ-
atedwith the frequency offlares and immunosuppression therapy
has been shown to decrease relapse rates (4). Conversely, the
long-term risks of immunosuppression can be substantial, par-
ticularly for young patients with AIH faced with the prospect of
decades of treatment (5).
The high relapse rate and variability in clinical guidelines may
complicate the decision and execution of immunosuppression
withdrawal in AIH (Table 1). In this review, we provide an
overview on the existing literature on stopping of AIH therapy




Uncertain benefits of maintenance immunosuppression
The benefits of induction therapy for AIH have been demon-
strated by multiple randomized controlled trials showing that
prednisone monotherapy or combination prednisone and aza-
thioprine therapy effectively induces remission and decreases
mortality (4). There have also been some investigations on al-
ternative AIH therapies including mycophenolate mofetil, cy-
closporine, tacrolimus, tumor necrosis factor inhibitors, and
ursodeoxycholic acid. Currently, these options should be con-
sidered second or third line therapies (2,6).
However, there are less data supporting the benefits of
maintenance therapy. There are 2 randomized trials examining
azathioprine monotherapy or combination azathioprine/
prednisone therapy including a total of 97 patients demonstrat-
ing high rates of remission in treated groups (4). The lack of
deaths in these studies precluded the assessment of the effect of
maintenance therapy on mortality. Given that relapses are asso-
ciated with liver-related complications and deaths, it has been
deduced that maintenance therapy reduces the risk of liver-
related death or transplantation in AIH, but this has never been
conclusively demonstrated (4).
Medication-related side effects
Corticosteroid-related side effects include cosmetic changes (e.g.,
weight gain, acne, hirsutism, and facial rounding), glucose in-
tolerance, osteoporosis, and lower health-related quality of life
(5,7). Budesonide therapymay reduce steroid-related side effects,
but it cannot be used in patients with cirrhosis and has less
established long-term efficacy data than prednisone/
prednisolone (2).
Azathioprine can cause mild myelosuppression, nausea,
rash, and fever (5). More severe but less common toxicities in-
clude severe cytopenias, pancreatitis, and hepatotoxicity. Fi-
nally, azathioprine has been linked with an increased risk of
malignancy, including skin cancer and lymphoma. Although
the absolute increase in the risk of malignancy from azathio-
prine is small, this association is particularly concerning for
young patients faced with the prospect of multiple decades of
treatment.
PROPOSED STRATEGY FOR IDENTIFYING DRUG
WITHDRAWAL CANDIDATES
Given the uncertain benefits and known harms of long-term
immunosuppression, withdrawal should be considered for many
patients with AIH. However, adequate patient selection is vital,
given the high frequency and potential dangers of relapse. This is
particularly true for the relatively high proportion of patients with
AIH with cirrhosis at baseline, for whom a relapse could be
deadly. Therefore, it is important to assess the patient’s risk of
relapse and ability to sustain another relapse before considering
drug withdrawal.
Before considering immunosuppression withdrawal, it is im-
portant to consider whether the patient may have a variant form
of AIH, with overlapping clinical, serological, or histological
characteristics of primary sclerosing cholangitis or primary bili-
ary cholangitis (2). Data on relapse rates and treatment response
in AIH may not be generalizable to these patients. Furthermore,
a patient’s liver transplant candidacy should be considered before
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initiating immunosuppression withdrawal, given that relapse
may increase the risk of liver failure (8).
How likely is a relapse in my patient?
There are several factors that clearly affect relapse risk (Figure 1)
(9). First, drug-induced AIH (DIAIH), most often related to
minocycline or nitrofurantoin use, portends a good prognosis.
DIAIH has biochemical and histologic features closely re-
sembling nondrug-related AIH but does not typically relapse
after immunosuppression is withdrawn if the culprit medication
is avoided (10).
Second, longer duration of therapy and shorter time to achieve
remission are associated with lower rates of relapse (4). In 1 large
series, patients with more than 4 years of continuous therapy had
a 67% probability of sustained response compared with 17%
among those treated for 2–4 years (11). In another study, relapse
occurred after medication withdrawal in nearly 90% of patients
who failed to achieve remission within 5 months (12).
Third, and perhaps the most important, those who demon-
strate biochemical and histologic remission before treatment
withdrawal are at lower risk for relapse compared with those who
have either had an incomplete response or treatment failure (1).
Normal liver enzymes and immunoglobulin G (IgG) levels are
necessary but potentially insufficient for confirming remission.
Over half of patients with normal biochemical testing will still
have evidence of interface hepatitis (1). Histologic remission
therefore remains an important treatment endpoint (12,13).
There are a number of other potential predictors of relapse risk
outlined in Figure 1 including psychological stress, patient age,
and coexisting autoimmune disease. In addition to autoantibody
Table 1. Treatment guidelines for immunosuppression withdrawal in autoimmune hepatitis
Minimum criteria for drug withdrawal Tapering recommendations
Lab monitoring during and after drug
withdrawal
AASLD (1) Normal AST or ALT,a total bilirubin, gamma-
globulin or IgG level, and normal liver histology
not exhibiting inflammatory activity. Treatment
should be continued for at least 24 mo after
achieving biochemical remission.
Gradual prednisone taper over a 6-wk period. ASTor ALT, total bilirubin, and gamma-globulin
levels at 3 wk intervals during and for 3mo after
drug withdrawal. Repeat laboratory
assessments thereafter every 6 mo for at least
1 yr and then every year lifelong.
EASL (2) Normal IgG and transaminases without
histological disease activity (HAI , 4).
Treatment should be continued for at least 3 yr
and for at least 2 yr after biochemical
normalization.
Stepwise reduction of immunosuppressive
agents. No further specifications.
Patients should be closely monitored
immediately after treatment withdrawal and
have lifelong surveillance. No further
specifications.
BSG (3) Normal transaminases and histologic
remission. Treatment should be continued for
at least 2 yr and for at least 12 mo after
normalization of transaminases.
Gradual prednisone taper of 2.5 mg/d each
month.
Monitoring of liver tests. No further
specifications.
AASLD, American Association for the Study of Liver Diseases; BSG, British Society of Gastroenterology; ALT, alanine aminotransferase; AST, aspartate aminotransferase;
EASL, the European Association for the Study of the Liver; HAI, hepatitis activity index; IgG, immunoglobulin G.
aNormal ALT ,25 for females and,33 for males (17).
Figure 1. Prognostic factors in assessing the risk of relapse after drug withdrawal in AIH. AIH, autoimmune hepatitis; ALT, alanine aminotransferase; AST,
aspartate aminotransferase; IgG, immunoglobulin G. Normal ranges for liver enzymes were obtained from the ACG Clinical Guideline for Evaluation of
Abnormal Liver Chemistries (17).
avoided in those with a previous relapse or evidence of significant
fibrosis/cirrhosis.
SUGGESTED APPROACH TO TREATMENTWITHDRAWAL
A closely monitored treatment withdrawal should be considered
in patients with at least 2 years of therapy, no previous relapses, no
clinical/biochemical/histologic evidence of ongoing in-
flammation or significant fibrosis and low risk of corticosteroid-
related side effects (Figure 2). If the decision is made to withdraw
therapy, there are no clear guidelines for how to safely taper
medications. If patients are on prednisone monotherapy, a slow
taper of 2.5 mg/d/mo can be followed (1,3). For patients on
azathioprine, some clinicians stop therapy completely while
others wean the dose gradually.
Although there is no clear consensus on how to taper therapy,
there are clear recommendations for monitoring patients after
drug withdrawal (1–3). Liver function and IgG testing should be
performed every 3weeks during the tapering phase and for at least
3 months after stopping therapy. Thereafter, laboratory moni-
toring should occur every 3 months for up to a year. If the
biochemical markers remain normal, they should be checked
every 6 months for 2–3 years, followed by annually. Periodic
noninvasivefibrosis assessment (e.g., transient elastography)may
also be considered (15). Although relapses tend to occur within
the first year after discontinuation, monitoring should continue
indefinitely because disease relapse can happen at any time (16).
CONCLUSION
In conclusion, AIH is a serious, lifelong disease that can cause
liver-related morbidity and mortality. Patients can achieve
Figure 2. Proposed algorithm for withdrawing drug therapy in AIH. AIH, autoimmune hepatitis; ALT, alanine aminotransferase; AST, aspartate amino-
transferase; IgG, immunoglobulinG;mHAI,modifiedhepatic activity index;ULN, upper limit of normal.Normal ranges for liver enzymeswere obtained from
the ACG Clinical Guideline for Evaluation of Abnormal Liver Chemistries (17).
and IgG levels, there are novel noninvasive markers that show 
promise in predicting treatment failure, including increased 
mean platelet volume and hypoalbuminemia (14). However, the 
role of noninvasive markers for the assessment of disease and 
response to therapy is controversial and continues to evolve. Fi-
nally, given that AIH epidemiology and phenotype differ 
according to ethnicity, there may be additional genetic, etiologi-
cal, or socioeconomic factors that influence disease course and 
relapse risk (2).
Is my patient healthy enough to experience a relapse?
Each relapse requires reinitiation of induction dose cortico-
steroids, which has several potential downstream consequences. 
Therefore, providers should proceed with caution when consid-
ering drug withdrawal in patients at increased risk for significant 
corticosteroid-related side effects. Such patient populations in-
clude those with osteoporosis or signs of metabolic syndrome, 
given that corticosteroids can reduce bone density and predispose 
to obesity, glucose intolerance, hypertension, and hyperlipidemia 
(5). Furthermore, withdrawal must be judiciously approached in 
those with underlying psychiatric comorbidities or emotional 
lability because steroid use has been correlated with anxiety and 
depression (7).
Patients who relapse often achieve remission with reinstitu-
tion of azathioprine and induction dose steroids, but each addi-
tional relapse increases the risk of fibrosis, liver-related 
complications, and death (8). The risk of significant fibrosis and 
liver-related complications increases significantly after a third 
relapse and poor outcomes occur almost exclusively in those with 
established cirrhosis (8,9). Therefore, drug withdrawal should be
remissionwith immunosuppressive therapy and should be placed
onmaintenance therapy for a minimum of 2 years except in cases
ofDIAIH. Long-term therapy beyond this has less certain benefits
and may lead to significant treatment-related side effects and
medication-related burden. A high proportion of patients with
AIH who stop therapy experience a relapse and associated mor-
bidity, but these risks can be minimized with appropriate patient
selection and vigilant postwithdrawal monitoring. Future in-
vestigation may focus on improving risk stratification tools and
developing therapies that alter the underlying immunologic
drivers of AIH.
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